Reflecting on the past year, we are grateful for the numerous achievements and milestones we've reached together. We wish all a happy and healthy New Year. Here's to a bright future ahead!
Poseida Therapeutics, Inc.
Biotechnology Research
San Diego, California 40,781 followers
The Capacity to Cure
About us
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com.
- Website
-
http://poseida.com/
External link for Poseida Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative Medicine, T-cells, Allogeneic, Oncology, Immuno-oncology, Immunology, Poseida, Cytotoxic T Lymphocytes, piggyBac®, piggyBac® DNA Modification System, Cas-CLOVER™, and TAL-CLOVER™
Locations
-
Primary
Get directions
9390 Towne Centre Dr
200
San Diego, California 92121, US
Employees at Poseida Therapeutics, Inc.
Updates
-
We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24! https://lnkd.in/e-S-tFeJ #CapacitytoCure #celltherapy
-
-
We’re thrilled to announce Poseida entered into a definitive agreement to be acquired by Roche Holdings, Inc. At the closing of the proposed transaction, Poseida and its employees will join the Roche Group and advance our innovative pipeline of non-viral, Tscm-rich CAR-T therapies and genetic medicines as part of Roche’s Pharmaceuticals Division. Details here: https://lnkd.in/gvbwFU7r #CapacitytoCure #celltherapy #CART #geneticmedicines
-
Learn more about our CEO, Kristin Yarema, Ph.D., her career in #biotech and her vision for the future of #allogeneic cell therapy and non-viral genetic medicines. All this and more in Biotech2050’s latest podcast out now: https://lnkd.in/dbXeNNn2 #CapacitytoCure #celltherapy #CART
-
Poseida Therapeutics, Inc. reposted this
Join us at our November A2I Coffee Club on November 21 from 6:30pm-7:30pm on Zoom! This time we will focus on the Science and Scope of CAR T-cell Therapy with two specialists from Poseida Therapeutics! Register at https://lnkd.in/gnyfbSpU or by scanning QR code on flyer. Visit AWIS.org for membership details and email A2i@AWISSD.org for more meeting info.
-
-
Tune into CGTLive’s latest interview with Bhagirathbhai Dholaria, MD, discussing Poseida’s #IMS2024 data on P-BCMA-ALLO1 in multiple myeloma: https://lnkd.in/eXCF_GcC
Dholaria spoke about the safety and efficacy results, highlighting the nonoccurrence of graft versus host disease in the treated patients and the 91% ORR in the enhanced lymphodepletion arm. Poseida Therapeutics, Inc. #mmsm #MultipleMyeloma #celltherapy Watch: https://lnkd.in/eXCF_GcC
Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
cgtlive.com
-
Our CEO, Kristin Yarema, Ph.D., will be providing a corporate presentation at Stifel’s 2024 Healthcare Conference on Monday, November 18. The presentation will be webcast live on our website at https://lnkd.in/euY5mmFc, with a replay available shortly thereafter. #CapacitytoCure #celltherapy #geneticmedicines
-
-
Poseida is going live at 10 am ET. Join our exciting #celltherapy R&D Day, where we’ll share the latest on our clinical and early-stage cell therapy programs targeting #oncology and #autoimmune disease: https://lnkd.in/e9a5C_eJ More details in today’s news: https://lnkd.in/esP6E_Uh #CapacitytoCure #allogeneic #CART
-
-
We are so proud to be recognized as a BioSpace Best Place to Work for the second year in a row! A big thanks to our dedicated, passionate, and patient-centric team for all their hard work and earning this recognition. More on what makes us a #bestplacetowork: https://lnkd.in/e5AC_YG7 #CapacitytoCure #PoseidaProud
-
-
Honoring the brave men and women who have served in the military today and every day. Your courage, sacrifice, and commitment to our nation inspires us all. Thank you for your service. #PoseidaProud #HonoringHeroes #CapacitytoCure
-